Achieve Life director granted stock options, RSUs

Achieve Life Sciences director Nancy R. Phelan received new equity awards.

Rhea-AI Filing Summary

Achieve Life Sciences director Nancy R. Phelan received new equity awards. She was granted stock options for 25,000 shares of common stock at an exercise price of $6.18 per share, expiring on July 27, 2036. These options vest 100% on the earlier of July 27, 2027 or immediately before the company’s 2027 annual stockholders’ meeting, subject to her continued service. She also received 16,700 Restricted Stock Units, each representing a contingent right to receive one share of common stock, with the same cliff-vesting schedule and service condition.

Insider Trade Summary

Grant/Award: 41,700 shares

Grant/Award 2 txns

Insider Phelan Nancy R.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00
Grant/Award	Restricted Stock Unit (RSU) F2, F3	16,700	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct); Restricted Stock Unit (RSU) — 16,700 contracts (Direct)

Footnotes (3)

1. F1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
3. F3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

Key Figures

Stock options granted: 25,000 shares Option exercise price: $6.18 per share Option expiration date: 2036-07-27 +5 more

8 metrics

Stock options granted 25,000 shares Stock Option (right to buy) grant to director Nancy R. Phelan on 2026-07-27

Option exercise price $6.18 per share Exercise price for 25,000 stock options granted on 2026-07-27

Option expiration date 2036-07-27 Expiration date of Nancy R. Phelan’s 25,000 stock options

RSUs granted 16,700 units Restricted Stock Unit grant to Nancy R. Phelan on 2026-07-27

Option vesting date trigger July 27, 2027 Cliff vesting on earlier of July 27, 2027 or date before 2027 annual meeting

RSU vesting date trigger July 27, 2027 RSUs vest 100% on earlier of July 27, 2027 or date before 2027 annual meeting

Options held after grant 25,000 options Total stock options reported following the transaction

RSUs held after grant 16,700 RSUs Total RSUs reported following the transaction

Key Terms

Stock Option (right to buy), Restricted Stock Unit (RSU), contingent right, vest 100%, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Restricted Stock Unit (RSU) financial

"security_title: Restricted Stock Unit (RSU)"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

contingent right financial

"Each RSU represents a contingent right to receive one share"

vest 100% financial

"The options vest 100% on the earlier of July 27, 2027"

annual meeting of stockholders financial

"immediately prior to the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Achieve Life Sciences (ACHV) director Nancy R. Phelan receive?

Nancy R. Phelan received a grant of 25,000 stock options and 16,700 Restricted Stock Units (RSUs). Both awards are tied to Achieve Life Sciences common stock and represent part of her director equity-based compensation.

What is the exercise price of Nancy Phelan’s new stock options at ACHV?

The new stock options granted to Nancy R. Phelan have an exercise price of $6.18 per share. She received options on 25,000 shares of Achieve Life Sciences common stock with this strike price.

When do Nancy Phelan’s Achieve Life Sciences stock options and RSUs vest?

Both the stock options and RSUs vest 100% on the earlier of July 27, 2027 or immediately before Achieve Life Sciences’ 2027 annual stockholders’ meeting, provided Nancy R. Phelan continues to serve the company through the vesting date.

What does each RSU granted to Nancy Phelan by ACHV represent?

Each RSU granted to Nancy R. Phelan represents a contingent right to receive one share of Achieve Life Sciences common stock upon settlement. She was awarded 16,700 RSUs under these terms.

What are Nancy Phelan’s post-grant holdings from this ACHV Form 4 filing?

Following these awards, Nancy R. Phelan holds 25,000 stock options and 16,700 RSUs as reported positions. These figures reflect the equity awards covered in this specific filing only.

When do Nancy Phelan’s Achieve Life Sciences stock options expire?

The stock options granted to Nancy R. Phelan expire on July 27, 2036. She may exercise up to 25,000 options at an exercise price of $6.18 per share before this expiration date, subject to vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 05:17 PM Accepted by SEC EDGAR 07/29/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Phelan Nancy R.

(Last) (First) (Middle)

22722 29TH DR. SE

SUITE 100

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.18	07/27/2026		A		25,000		(1)	07/27/2036	Common Stock	25,000	$0	25,000	D
Restricted Stock Unit (RSU)	(2)	07/27/2026		A		16,700		(3)	07/27/2036	Common Stock	16,700	$0	16,700	D

Explanation of Responses:

1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.

3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

	Sandra Thomson as attorney-in-fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)